Advancing Bacterial Diagnostic DevelopmentRegister
Contact InformationLuke Durocher
Rising antimicrobial resistance remains a top global public health threat and efforts to support novel antibiotic development and availability are more critical and timely than ever. As the ongoing pandemic centers national and global conversations around actions to prevent and combat future infectious disease threats, the time to take action against AMR is now.
About this Webinar
Policymakers, researchers, and others combating AMR Duke-Margolis are invited to join Duke-Margolis for a public webinar to learn about strategies to support bacterial diagnostic development, market access, and clinical utility.
Duke-Margolis Center Director Dr. Mark McClellan and Senior Research Director Dr. Marianne Hamilton Lopez will moderate two panel discussions during the webinar. Panelists will discuss the clinical evidence that diagnostic developers generate for regulatory clearance. Specifically, strategies to improve diagnostic development and evidence generation, and how the evidence available influences how clinicians use diagnostics and whether diagnostics are covered by payers. Panelists will then discuss strategies to sustain the bacterial diagnostics market with administrative and regulatory actions or incentives, innovative payment mechanisms, and diagnostic stewardship.
Register today to learn about the barriers limiting critical bacterial diagnostic development and what might be done to advance bacterial diagnostic development and combat rising AMR.
This webinar will be recorded and files will be posted to this page, typically within three to five business days.
This webinar is sponsored by the Wellcome Trust.
Duke-Margolis Policy Research to Address Drug-Resistant Infections
Duke-Margolis publishes policy research on promising approaches and recommendations to combat AMR and rising drug-resistant infections.
See our publications through the links below to learn more about post-market incentive strategies to support the development of innovative antibiotics and the use of a subscription model in Medicare to delink US antibiotic payments.